Compare IMMP & SFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMMP | SFST |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 429.7M |
| IPO Year | 2012 | 2012 |
| Metric | IMMP | SFST |
|---|---|---|
| Price | $0.61 | $56.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.50 | ★ $64.00 |
| AVG Volume (30 Days) | ★ 22.9M | 137.2K |
| Earning Date | 04-23-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.76 |
| EPS | N/A | ★ 3.72 |
| Revenue | N/A | ★ $6,282,000.00 |
| Revenue This Year | $445.09 | $10.47 |
| Revenue Next Year | N/A | $12.19 |
| P/E Ratio | ★ N/A | $15.53 |
| Revenue Growth | N/A | ★ 12.99 |
| 52 Week Low | $0.29 | $32.90 |
| 52 Week High | $3.53 | $62.00 |
| Indicator | IMMP | SFST |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 51.27 |
| Support Level | $0.29 | $50.36 |
| Resistance Level | $1.89 | $56.73 |
| Average True Range (ATR) | 0.08 | 1.79 |
| MACD | 0.12 | 0.08 |
| Stochastic Oscillator | 42.48 | 45.17 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.